ZB-131 by ZielBio for Ovarian Cancer: Likelihood of Approval
ZB-131 is under clinical development by ZielBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II …
Sudocetaxel zendusortide by Theratechnologies for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Sudocetaxel zendusortide is under clinical development by Theratechnologies and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to …
Dexamethasone sodium phosphate by AVM Biotechnology for Mantle Cell Lymphoma: Likelihood of Approval
Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Mantle Cell Lymphoma. According …
Ociperlimab by BeiGene for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to …
VAXINIA by Imugene for Metastatic Melanoma: Likelihood of Approval
VAXINIA is under clinical development by Imugene and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I …
VAXINIA by Imugene for Pancreatic Cancer: Likelihood of Approval
VAXINIA is under clinical development by Imugene and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I …
IMSA-101 by ImmuneSensor Therapeutics for Uveal Melanoma: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase …
Rilvegostomig by AstraZeneca for Hepatocellular Carcinoma: Likelihood of Approval
Rilvegostomig is under clinical development by AstraZeneca and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II …
Inaticabtagene autoleucel by Juventas Cell Therapy for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Inaticabtagene autoleucel is under clinical development by Juventas Cell Therapy and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. …
Golcadomide hydrochloride by Bristol-Myers Squibb for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According …
Golcadomide hydrochloride by Bristol-Myers Squibb for Primary CNS Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Primary CNS Lymphoma. According to …
Golcadomide hydrochloride by Bristol-Myers Squibb for Follicular Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Follicular Lymphoma. According to GlobalData, …
Golcadomide hydrochloride by Bristol-Myers Squibb for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diffuse Large B-Cell Lymphoma. According …
Golcadomide hydrochloride by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval
Golcadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, …
Dazostinag by Takeda Pharmaceutical for Oropharyngeal Cancer: Likelihood of Approval
Dazostinag is under clinical development by Takeda Pharmaceutical and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase …